LONDON, July 20, 2016 /PRNewswire/ --
The IP Life Sciences Exchange put together the report "Under the Microscope" to explore the most pressing issues facing in-house counsel in the life sciences sector in 2016: http://bit.ly/29VhuuR
This report provides you with a range of insights across biodiversity, the impact of Brexit on the Unitary Patent, the importance of IP awareness when linking IP strategy to the business' strategy and the impact of patent eligibility to biotech. Michael Kock, Head of IP from Syngenta stresses the need to transform the IP system in biodiversity into something which is more open, more transparent and makes innovation more accessible. Post Brexit, this piece by Rachel Fetches, Intellectual property litigator and Partner at HGF Law then seeks to get to the bottom of the impact to the UP and UPC, including looking at the grant of European patents. Claudia Hallebach, Head of R&D Legal Affairs and Intellectual Property, bei KWS SAAT AG, then highlights the importance of IP awareness to your in-house team, which should not only exist in formal procedures and processes, but should be one of the driving factors for research, development and commercialisation activities. Lastly, Christoph Rehfuess, European Patent Attorney Head of IP, Sotio a.s details the importance of clarity in patent eligibility for biotechs in 2016.
When asking Michael Kock, Head of IP from Syngenta what he thinks will need to happen to protect the future of biotech inventions, he replied: "We need to find a way to transform the IP system in these areas into something which is more open, more transparent and makes innovation more accessible, so that we get the broader society and political support to back these kind of innovations."
Similarly, the importance of innovation is strikingly clear to Claudia Hallebach, Head of R&D Legal Affairs and Intellectual Property, bei KWS SAAT AG, who believes that "Increasing IP awareness also translates into identifying IP value capture opportunities, which in itself does a lot in changing company cultures on the importance of IP."
Get the complete insider perspective to maximize innovation, growth and the value of your pharmaceutical and biotechnology IP by downloading the full free report here: http://bit.ly/29VhuuR
Find out more about patentability issues, biodiversity, unitary patent, and alignment of IP strategy.